Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Myeloproliferative diseases]

Z Adam1, J Vorlícek, M Matýsková

  • 1II. interní klinika FNsP, Brno-Bohunice.

Vnitrni Lekarstvi
|October 1, 1996
PubMed
Summary
This summary is machine-generated.

Myeloproliferative neoplasms (MPNs) encompass several conditions with varying prognoses. Treatment strategies are tailored to specific MPNs, focusing on managing symptoms and improving patient survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cutaneous diseases caused by monoclonal immunoglobulin and/or free light chains (monoclonal gammopathy of cutaneous significance).

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2026
Same author

Changes in hemostasis and other disorders caused by monoclonal immunoglobulin and/or free light chains.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2026
Same author

Treatment of Castleman disease from the perspective of the year 2026.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2026
Same author

Polyclonal hypergammaglobulinemia, infiltration of the salivary glands, lymphadenopathy, and kidney damage - Mikulicz's disease, Sjögren's syndrome, or Castleman's disease? Case report and overview of differential diagnosis and treatment.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2026
Same author

Monoclonal gammopathy of clinical significance - a group name for diseases caused by monoclonal immunoglobulin and/ or free light chains. A change in the approach to non-malignant gammopathies.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2025
Same author

Precision medicine in hemato-oncology - treatment of refractory multiple myeloma with massive extramedullary involvement using BRAF/ MEK inhibitors.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2025
Same journal

Pharmacological profile of mepolizumab.

Vnitrni lekarstvi·2023
Same journal

Atypical form of Goodpasture's disease.

Vnitrni lekarstvi·2023
Same journal

Differentiated thyroid cancer - possible risks of treatment, suppressive therapy and adherence to current recommendations.

Vnitrni lekarstvi·2023
Same journal

Dyslipidemia - the known unknown.

Vnitrni lekarstvi·2023
Same journal

Internal comorbidities and complications of multiple sclerosis therapy - don't be caught off guard!

Vnitrni lekarstvi·2023
Same journal

Implications of highly suppressive treatment HIV infection.

Vnitrni lekarstvi·2023
See all related articles

Area of Science:

  • Hematology
  • Oncology

Context:

  • Myeloproliferative diseases (MPDs) are a group of disorders characterized by the overproduction of myeloid cells.
  • These include primary polycythemia, primary thrombocytosis, primary myelofibrosis, and chronic myeloid leukemia, each with distinct clinical courses and survival rates.

Purpose:

  • To provide an overview of the clinical presentation, diagnostic challenges, and evolving therapeutic approaches for myeloproliferative diseases.
  • To highlight differences in survival and treatment modalities among primary polycythemia, primary thrombocytosis, primary myelofibrosis, and chronic myeloid leukemia.

Summary:

  • Primary polycythemia and primary thrombocytosis generally have a survival exceeding 10 years, managed with phlebotomy or cytoreductive agents. Primary myelofibrosis and chronic myeloid leukemia have shorter survival (around 5 years) and may require more intensive supportive care or, in the case of CML, stem cell transplantation.

Related Experiment Videos

  • Treatment for primary thrombocytosis aims to normalize platelet counts to mitigate hemorrhagic and thrombotic risks, using similar medications as for primary polycythemia.
  • Therapeutic strategies for primary myelofibrosis and chronic myeloid leukemia focus on reducing pathological cell populations in the bone marrow.

    • Impact:

    • This review aims to update clinicians on recent advancements in managing these complex hematological malignancies.
    • Understanding the differential diagnosis and therapeutic shifts is crucial for optimizing patient outcomes in myeloproliferative diseases.